



Semarak International Journal of Public Health and Primary Care

Journal homepage:
<https://semarakilmu.my/index.php/sijphpc/index>
ISSN: 3083-8401



Insulin Index – A “Decretin” Approach in the Era of “Incretin”

Sriwathi Angeline Hendricks¹, Bhuwaneswaran Vijayam^{1,2,3,4,*}

¹ Independent Researcher, 81300 Johor Bahru, Johor, Malaysia

² Newcastle University Medicine Malaysia (NUMed), Iskandar Puteri, 79200 Johor, Malaysia

³ Department of Clinical Medicine, Newcastle University Medicine Malaysia (NUMed), Iskandar Puteri, 79200 Johor, Malaysia

⁴ Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE1 7RU, United Kingdom

ARTICLE INFO

Article history:

Received 23 July 2025

Received in revised form 15 August 2025

Accepted 31 August 2025

Available online 30 September 2025

Keywords:

Decretin; incretin; insulin index;
insulinaemic index; insulinemic index;
entero-insular; GLP-1; hyperinsulinemia

ABSTRACT

Obesity and diabetes have become prevalent health issues globally, with significant impacts on the Asian population, including Southeast Asia. This paper explores the concept of "decretin," which focuses on minimising insulin secretion through dietary strategies. This concept is in contrast to the incretin-based approaches that enhance insulin release. The Insulin Index (II), which measures the insulin response to various foods in comparison to a reference food, is proposed as a tool that may be manipulated for the preferred decretin action. Decretin involves dietary strategies to reduce insulin excursion, potentially offering therapeutic benefits for insulin resistance and diabetes. This paper emphasises the discussion of foods with low II values, insulin responses, and the strategies for insulin resistance and hyperinsulinemia. This may open further research pathways on the decretin action to develop tailored dietary guidelines for diabetes management in the Southeast Asian region.

1. Introduction

In today's world, obesity and diabetes have both become common household names. The Asian population is no stranger to these medical conditions. In fact, China, India, and Pakistan held the top three spots with the largest number of diabetics worldwide as of 2021 [1]. In Southeast Asia (SEA), Brunei and Malaysia had the highest prevalence of obesity of more than 50% [2,3]. Malaysia in particular saw a rise in 2019 compared to previous national surveys conducted in 2011 and 2015, respectively [3].

The concept of "incretin" has gained significant attention in recent times in the context of obesity, weight loss and diabetes management [4-6]. Presently, obesity management is centered around bariatric surgery, GLP-1 receptor agonists, sympathomimetic agents, opioid antagonist with dopamine and noradrenaline reuptake inhibitor, lipase inhibitors, physical activity, and the combination of pharmacotherapy with other treatment modalities [7]. Nevertheless, GLP-1 receptor agonists such as semaglutide which is essentially an incretin, have appealed to many obese patients and owes its growing popularity to celebrity endorsements and its effectiveness in causing weight loss [8].

* Corresponding author.

E-mail address: bhuwaneswaran.vijayam@newcastle.edu.my

The concept of "decretin", on the other hand, offers an intriguing alternative approach. There is an apparent research gap where the focus has been on increasing insulin secretion to enable better blood glucose control, when excess insulin is in fact detrimental in various ways. This can be explained by hyperinsulinaemic states which carry the burden of multiple disease states including but not limited to insulin resistance, cardiovascular diseases, cerebrovascular events, and obesity [9,10]. Hence this research has a significant role of realigning the focus towards tackling insulin resistance through a decretin concept of taming insulin spikes. This short communication paper aims to explore the concept of the Insulin Index (II) and its potential as a tool for managing diabetes, particularly in SEA.

2. Throwing Light on Decretin

Decretin, an emerging concept, refers to minimising insulin secretion, which includes dietary strategies to downscale insulin response to food intake, in contrast to the incretin-based approaches that enhance insulin release. The term decretin was used back in 1997 by Ensink *et al.*, [14] and was later discussed separately by previous researchers [11-13]. To our best knowledge all these scientific discussions were from animal models and the concept in human endocrinology is yet to be established. However, the concept of decretin is gaining traction as a potential therapeutic approach to manage insulin resistance and diabetes [15-17].

Current focus on decretin only involves limostatin and neuromedin U (NMU) that suppress insulin secretion [12,18]. Its multiple roles revolve around food intake suppression, energy expenditure and locomotor activity stimulation, improvement in glucose metabolism, increase in BAT thermogenesis, and decrease in both adiposity and body weight [18]. We believe that the unique physiologic, endocrine and neurological properties of the decretin action would result in an alternative means to the desired endogenous insulin suppression.

3. Hyperinsulinaemia – The Ticking Timebomb

Hyperinsulinaemia, which was discussed extensively by Kraft *et al.*, [21] and Croft *et al.*, [20] is a known early biomarker for metabolic dysfunction and metabolic disease. It is state of chronically elevated blood insulin owing to insulin secretion dysregulation with or without poor clearance, and in the absence of hypoglycaemia [22]. A substantial body of evidence has suggested that hyperinsulinaemia is well-linked to a myriad of medical conditions such as Type 2 diabetes, obesity, cardiovascular disease, cerebrovascular events, premature deaths, and even malignancies [9,10].

4. Insulin Index and Decretin: Mechanism of Action

The Insulin Index (II) is a measure that quantifies the insulin excursion elicited by various foods in comparison to a reference food such as bread or glucose [23]. While the Glycaemic Index (GI), which measures blood glucose levels, the II provides insight into how different foods impact insulin secretion [23–28]. For perspective, the differences seen between the post-prandial blood insulin and glucose excursion curves of watermelon are showcased in Figure 1. The post-prandial glucose's incremental area under the curve (iAUC) of the test food, watermelon in this case, appears to be well below that of the reference food which is glucose. This results in a low to moderate GI value of watermelon. On the contrary, the post-prandial insulin's iAUC of watermelon appears to be almost that of the reference food. This indicates that the II of watermelon is close to 100. Figure 2 shows the hypothesised decretin action of the food with low II on both the glucose and insulin excursions after

consumption. The incretin food chosen for the illustration has both low insulin and glucose excursion. This was compared with a standard reference food in clinical nutrition and the incretin response as well. The orange and light blue arrows show the incretin effect and incretin action, respectively. A previous compilation of II and GI values showed that less than 1% of food with II lower than 50 were in the high GI group [26]. In addition, there were no representation in the medium and high GI group when food had II lower than 20 [26]. Taking account, the compilation was limited to 121 foods, we hypothesise that incretin action would lower both the insulin and glucose.




Fig. 1. The difference in post-prandial excursion curves between blood insulin and glucose for watermelon, and its respective II and GI values (data adapted from Ryu et al., 2012) [29]




Fig. 2. The incretin effect and incretin action on both insulin and glucose excursions

While there are neither clinical cut-off points nor ranges for low II, foods with low II values cause smaller insulin excursions. The mechanism involves lowering of overall insulin excursion, inflammation and reduced deposits of ectopic fats and reduce occurrence of non-alcoholic fatty liver

disease (NAFLD) and atherosclerosis [15,29,30]. The recent II compilation from Hendricks et al., shows that the insulin excursions vary significantly between foods, suggesting that selecting foods with low II may play a role in managing insulin spikes effectively. To date, two trials have examined the effects of a low II diet on health outcomes [31,32]. These studies suggest promising results as they have explored the lowering of insulin excursion and reducing the risk of being overweight [31,32].

5. The Decretin Effect of Low II Foods

Creating a comprehensive low II food list requires identifying foods that elicit minimal insulin excursions. These foods typically include nuts, seeds, fats, and certain protein sources. Figure 3 is a simplified diagram of some foods within specific II cutoff points based on a recent II compilation [15].




Fig. 3. Some foods that are below the II of 50. Illustration modified from Hendricks *et al.*, [15]

Interestingly, we found that most Mediterranean foods, characterised by high consumption of fish, nuts, and healthy fats, are likely to have a low II. We hypothesise that, decretin action may have contributed to the health benefits associated with the Mediterranean diet which has yet to be probed in the field of clinical nutrition [33]. From our food II compilation, salient Mediterranean foods such as durum wheat-based pasta, tomato pasta sauce, wine, cheese and olive oil had lower II than other foods [15].

On the other hand, certain foods have a high capacity to spike insulin levels, such as sugary snacks, refined carbohydrates, vegetables, fruits, and dairy products. Identifying and minimising these foods is crucial for managing the insulin spikes post-meal [15,23].

6. The Southeast Asian Diabetic Clusters' Dilemma

In recent years, clustering diabetes has been revolutionary in providing more insightful, precise and personalised management [34,35]. In SEA, the dilemma of managing diabetes is compounded by a lack of region-specific II data and the prevalence of incretin-based medications. The minimally populated II lists pose a challenge for developing dietary guidelines tailored to local populations. In SEA, diabetes clusters, predominantly related to obesity and insulin resistance (IR) [36,37].

We speculate that there is a role of incretin to "tame" the hypersulinaemic responses. Although there are no clinical cut-off points for low-, medium-, and high-II, foods that exert low insulin response may potentiate the incretin action. To back our hypothesis, we have discussed in this manuscript's earlier subtopic about the II-GI relationship from Bao *et al.*, [26]. Future studies should be carried out to test this hypothesis thus strengthening or nullifying the incretin hypothesis.

7. When Incretin Interacts

The impact of the insulin on other hormones, such as glucagon and may provide deeper insights into the holistic management of diabetes [6,38]. It is now understood that one of the many strategies for regenerating the pancreatic beta-cell, reducing adipogenesis and inflammation of both the pancreas and liver is to re-establish the loss oscillatory properties of insulin and glucagon [39-45]. From an anorexic perspective, the incretin mimics the incretin effect [46-51]. This was also seen in NMU as discussed elsewhere [18]. Foods with low II also affect ghrelin, cholecystokinin (CCK), leptin, and satiety owing further to the anorexic effect [48,52-54]. It is crucial to understand the entero-insular effect of these hormones [45].

8. Conclusion

The concept of the II and the incretin approach seems appealing and entrenched from our discussion. Both offer promising avenues for managing diabetes, especially in SEA region where there are high prevalence of obesity and insulin resistance. It is of paramount importance for future research to expand on the incretin action of food II for as an adjuvant dietary guideline for diabetes management.

Acknowledgement

This research was funded by Newcastle University Medicine Malaysia (NUMed) NIRG 226900-IG9.

References

- [1] D.J. Magliano, E.J. Boyko, IDF Diabetes Atlas 10th, IDF Diabetes Atlas, 10th Edition (2021) 1–764.
- [2] Ong, Sok King, Daphne Teck Ching Lai, Justin Yun Yaw Wong, Khairil Azhar Si-Ramlee, Lubna Abdul Razak, Norhayati Kassim, Zakaria Kamis, and David Koh. "Cross-sectional STEPwise approach to surveillance (STEPS) population survey of noncommunicable diseases (NCDs) and risk factors in Brunei Darussalam 2016." *Asia Pacific Journal of Public Health* 29, no. 8 (2017): 635-648. <https://doi.org/10.1177/1010539517738072>
- [3] Chong, Chean Tat, Wai Kent Lai, Syafinaz Mohd Sallehuddin, and Shubash Shander Ganapathy. "Prevalence of overweight and its associated factors among Malaysian adults: Findings from a nationally representative survey." *PLoS One* 18, no. 8 (2023): e0283270. <https://doi.org/10.1371/journal.pone.0283270>
- [4] Seino, Yutaka, Mitsuo Fukushima, and Daisuke Yabe. "GIP and GLP-1, the two incretin hormones: similarities and differences." *Journal of diabetes investigation* 1, no. 1-2 (2010): 8-23. <https://doi.org/10.1111/j.2040-1124.2010.00022.x>
- [5] S. Roy, S. Chakraborty, The Incretin Axis-Revisiting the Basics: A Review, La Prensa Medica Argentina 105 (2019). <https://doi.org/10.47275/0032-745X-123>

- [6] Nauck, Michael A., and Timo D. Müller. "Incretin hormones and type 2 diabetes." *Diabetologia* 66, no. 10 (2023): 1780-1795. <https://doi.org/10.1007/s00125-023-05956-x>
- [7] Lee, Phong Ching, Chin Hong Lim, Ravishankar Asokkumar, and Marvin Wei Jie Chua. "Current treatment landscape for obesity in Singapore." *Singapore Medical Journal* 64, no. 3 (2023): 172-181. <https://doi.org/10.4103/singaporemedj.SMJ-2022-216>
- [8] Teneo Insights, The Multi-Sector Impacts of GLP-1RA Drugs, (2024).
- [9] Diener, Hans-Christoph, and Graeme J. Hankey. "Primary and secondary prevention of ischemic stroke and cerebral hemorrhage: JACC focus seminar." *Journal of the American College of Cardiology* 75, no. 15 (2020): 1804-1818. <https://doi.org/10.1016/j.jacc.2019.12.072>
- [10] Janssen, Joseph AMJL. "Hyperinsulinemia and its pivotal role in aging, obesity, type 2 diabetes, cardiovascular disease and cancer." *International journal of molecular sciences* 22, no. 15 (2021): 7797. <https://doi.org/10.1126/scisignal.aaa8672>
- [11] Gough, Nancy R. "Finding the incretin hormone." *Science Signaling* 8, no. 363 (2015): ec29-ec29. <https://doi.org/10.1126/scisignal.aaa8672>
- [12] Alfa, Ronald W., Sangbin Park, Kathleen-Rose Skelly, Gregory Poffenberger, Nimit Jain, Xueying Gu, Lutz Kockel et al. "Suppression of insulin production and secretion by a incretin hormone." *Cell metabolism* 21, no. 2 (2015): 323-334. <https://doi.org/10.1016/j.cmet.2015.01.006>
- [13] Crunkhorn, Sarah. "Novel incretin hormone identified." *Nature Reviews Drug Discovery* 14, no. 4 (2015): 238-238. <https://doi.org/10.1038/nrd4601>
- [14] Ensink, John W., Robin E. Vogel, Ellen C. Laschansky, Donna J. Koerker, Ronald L. Prigeon, Steven E. Kahn, and David A. D'Alessio. "Endogenous somatostatin-28 modulates postprandial insulin secretion. Immunoneutralization studies in baboons." *The Journal of clinical investigation* 100, no. 9 (1997): 2295-2302. <https://doi.org/10.1172/JCI119767>
- [15] Hendricks, Sriwathi Angeline, Mugabe Jean Paul, Yuganeswary Subramaniam, and Bhuwaneswaran Vijayam. "A collectanea of food insulinaemic index: 2023." *Clinical Nutrition ESPEN* 63 (2024): 92-104. <https://doi.org/10.1016/j.clnesp.2024.06.017>
- [16] Vijayam, Bhuwaneswaran, M. B. Malarvili, Muhammad Faiz Md Shakhhi, Nashuha Omar, and Asnida Abdul Wahab. "Effect of short-term ketogenic diet on end-tidal carbon dioxide." *Clinical Nutrition ESPEN* 42 (2021): 124-131. <https://doi.org/10.1016/j.clnesp.2021.02.005>
- [17] Ebbeling, Cara B., Henry A. Feldman, Gloria L. Klein, Julia MW Wong, Lisa Bielak, Sarah K. Steltz, Patricia K. Luoto, Robert R. Wolfe, William W. Wong, and David S. Ludwig. "Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: randomized trial." *bmj* 363 (2018). <https://doi.org/10.1136/bmj.k4583>
- [18] Botticelli, Luca, Emanuela Micioni Di Bonaventura, Fabio Del Bello, Gianfabio Giorgioni, Alessandro Piergentili, Wilma Quaglia, Alessandro Bonifazi, Carlo Cifani, and Maria Vittoria Micioni Di Bonaventura. "The neuromedin U system: Pharmacological implications for the treatment of obesity and binge eating behavior." *Pharmacological Research* 195 (2023): 106875. <https://doi.org/10.1016/j.phrs.2023.106875>
- [19] Cooper, Isabella D., Kenneth H. Brookler, and Catherine AP Crofts. "Rethinking fragility fractures in type 2 diabetes: The link between hyperinsulinaemia and osteofragilitas." *Biomedicine* 9, no. 9 (2021): 1165. <https://doi.org/10.3390/biomedicine9091165>
- [20] Crofts, Catherine, Grant Schofield, Caryn Zinn, Mark Wheldon, and Joseph Kraft. "Identifying hyperinsulinaemia in the absence of impaired glucose tolerance: An examination of the Kraft database." *Diabetes research and clinical practice* 118 (2016): 50-57. <https://doi.org/10.1016/j.diabres.2016.06.007>
- [21] Kraft, Joseph R. "Detection of diabetes mellitus in situ (occult diabetes)." *Lab med* 6, no. 2 (1975): 10-22. <https://doi.org/10.1093/labmed/6.2.10>
- [22] Thomas, Dylan D., Barbara E. Corkey, Nawfal W. Istfan, and Caroline M. Apovian. "Hyperinsulinemia: an early indicator of metabolic dysfunction." *Journal of the Endocrine Society* 3, no. 9 (2019): 1727-1747. <https://doi.org/10.1210/je.2019-00065>
- [23] Holt, S. H., J. C. Miller, and Peter Petocz. "An insulin index of foods: the insulin demand generated by 1000-kJ portions of common foods." *The American journal of clinical nutrition* 66, no. 5 (1997): 1264-1276. <https://doi.org/10.1093/ajcn/66.5.1264>
- [24] Brouns, F., I. Bjorck, K. N. Frayn, A. L. Gibbs, V. Lang, G. Slama, and T. M. S. Wolever. "Glycaemic index methodology." *Nutrition research reviews* 18, no. 1 (2005): 145-171. <https://doi.org/10.1079/NRR2005100>
- [25] Bell, Kirstine J., Jiansong Bao, Peter Petocz, Stephen Colagiuri, and Jennie C. Brand-Miller. "Validation of the food insulin index in lean, young, healthy individuals, and type 2 diabetes in the context of mixed meals: an acute randomized crossover trial." *The American Journal of Clinical Nutrition* 102, no. 4 (2015): 801-806. <https://doi.org/10.3945/ajcn.115.112904>

- [26] Bao, Jiansong, Fiona Atkinson, Peter Petocz, Walter C. Willett, and Jennie C. Brand-Miller. "Prediction of postprandial glycemia and insulinemia in lean, young, healthy adults: glycemic load compared with carbohydrate content alone." *The American journal of clinical nutrition* 93, no. 5 (2011): 984-996. <https://doi.org/10.3945/ajcn.110.005033>
- [27] Bell, Kirstine J., Peter Petocz, Stephen Colagiuri, and Jennie C. Brand-Miller. "Algorithms to improve the prediction of postprandial insulinaemia in response to common foods." *Nutrients* 8, no. 4 (2016): 210. <https://doi.org/10.3390/nu8040210>
- [28] Strydom, Hildegard, Elizabeth Delport, Jane Muchiri, and Zelda White. "The application of the food insulin index in the prevention and management of insulin resistance and diabetes: A scoping review." *Nutrients* 16, no. 5 (2024): 584. <https://doi.org/10.3390/nu16050584>
- [29] Kawano, Yuki, and David E. Cohen. "Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease." *Journal of gastroenterology* 48, no. 4 (2013): 434-441. <https://doi.org/10.1007/s00535-013-0758-5>
- [30] Wolosowicz, Marta, Slawomir Prokopiuk, and Tomasz W. Kaminski. "Recent advances in the treatment of insulin resistance targeting molecular and metabolic pathways: fighting a losing battle?." *Medicina* 58, no. 4 (2022): 472. <https://doi.org/10.3390/medicina58040472>
- [31] Caferoglu, Zeynep, Busra Erdal, Leyla Akin, and Selim Kurtoglu. "Breakfast and dinner insulin index and insulin load in relation to overweight in children and adolescents." *European Journal of Nutrition* 60, no. 5 (2021): 2819-2829. <https://doi.org/10.1007/s00394-020-02478-9>
- [32] Bell, Kirstine. "Clinical application of the food insulin index to diabetes mellitus." (2014).
- [33] Estruch, Ramón, Emilio Ros, Jordi Salas-Salvadó, Maria-Isabel Covas, Dolores Corella, Fernando Arós, Enrique Gómez-Gracia et al. "Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts." *New England journal of medicine* 378, no. 25 (2018): e34. <https://doi.org/10.1056/NEJMoa1800389>
- [34] 田辺隼人. "Factors associated with risk of diabetic complications in novel cluster-based diabetes subgroups: a Japanese retrospective cohort study/Burden of undiagnosed type 2 diabetes in diabetic kidney disease: a Japanese retrospective cohort study." PhD diss., Fukushima Medical University, 2021.
- [35] Omar, Nashuha, Nisha Nadhira Nazirun, Bhuwaneswaran Vijayam, Asnida Abdul Wahab, and Hana Ahmad Bahuri. "Diabetes subtypes classification for personalized health care: A review." *Artificial Intelligence Review* 56, no. 3 (2023): 2697-2721. <https://doi.org/10.1007/s10462-022-10202-8>
- [36] Wang, Jiexun, Jian-Jun Liu, Resham L. Gurung, Sylvia Liu, Janus Lee, Yiamunaa M, Keven Ang et al. "Clinical variable-based cluster analysis identifies novel subgroups with a distinct genetic signature, lipidomic pattern and cardio-renal risks in Asian patients with recent-onset type 2 diabetes." *Diabetologia* 65, no. 12 (2022): 2146-2156. <https://doi.org/10.1007/s00125-022-05741-2>
- [37] Chan, Juliana CN, Vasanti Malik, Weiping Jia, Takashi Kadowaki, Chittaranjan S. Yajnik, Kun-Ho Yoon, and Frank B. Hu. "Diabetes in Asia: epidemiology, risk factors, and pathophysiology." *Jama* 301, no. 20 (2009): 2129-2140. <https://doi.org/10.1001/jama.2009.726>
- [38] Nauck, Michael A., Daniel R. Quast, Jakob Wefers, and Andreas FH Pfeiffer. "The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update." *Diabetes, Obesity and Metabolism* 23 (2021): 5-29. <https://doi.org/10.1111/dom.14496>
- [39] Sharma, Anu, Ron T. Varghese, Meera Shah, Chiara Dalla Man, Claudio Cobelli, Robert A. Rizza, Kent R. Bailey, and Adrian Vella. "Impaired insulin action is associated with increased glucagon concentrations in nondiabetic humans." *The Journal of Clinical Endocrinology & Metabolism* 103, no. 1 (2018): 314-319. <https://doi.org/10.1210/jc.2017-01197>
- [40] Banarer, Salomon, Veronica P. McGregor, and Philip E. Cryer. "Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response." *Diabetes* 51, no. 4 (2002): 958-965. <https://doi.org/10.2337/diabetes.51.4.958>
- [41] Menge, Björn A., Lena Grüber, Signe M. Jørgensen, Carolyn F. Deacon, Wolfgang E. Schmidt, Johannes D. Veldhuis, Jens J. Holst, and Juris J. Meier. "Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes." *Diabetes* 60, no. 8 (2011): 2160-2168. <https://doi.org/10.2337/db11-0251>
- [42] Taylor, R. "Banting Memorial Lecture 2012 Reversing the twin cycles of Type 2 diabetes." *Diabetic medicine* 30, no. 3 (2013): 267-275. <https://doi.org/10.1111/dme.12039>
- [43] Taylor, Roy, Ahmad Al-Mrabeh, and Naveed Sattar. "Understanding the mechanisms of reversal of type 2 diabetes." *The lancet Diabetes & endocrinology* 7, no. 9 (2019): 726-736. [https://doi.org/10.1016/S2213-8587\(19\)30076-2](https://doi.org/10.1016/S2213-8587(19)30076-2)
- [44] Taylor, Roy, Ahmad Al-Mrabeh, Sviatlana Zhyzhneuskaya, Carl Peters, Alison C. Barnes, Benjamin S. Aribisala, Kieren G. Hollingsworth, John C. Mathers, Naveed Sattar, and Michael EJ Lean. "Remission of human type 2 diabetes

- requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery." *Cell metabolism* 28, no. 4 (2018): 547-556. <https://doi.org/10.1016/j.cmet.2018.07.003>
- [45] Malaguarnera, Roberta, Alessandra Scamporrino, Agnese Filippello, Stefania Di Mauro, Alessandro Minardo, Francesco Purrello, and Salvatore Piro. "The entero-insular axis: a journey in the physiopathology of diabetes." *Exploration of Medicine* 1, no. 6 (2020): 364-376. <https://doi.org/10.37349/emed.2020.00025>
- [46] Holt, S. H., Brand Miller JC, and P. Petocz. "Interrelationships among postprandial satiety, glucose and insulin responses and changes in subsequent food intake." *European journal of clinical nutrition* 50, no. 12 (1996): 788-797.
- [47] Holt, Susanne HA, and Janette Brand Miller. "Increased insulin responses to ingested foods are associated with lessened satiety." *Appetite* 24, no. 1 (1995): 43-54. [https://doi.org/10.1016/S0195-6663\(95\)80005-0](https://doi.org/10.1016/S0195-6663(95)80005-0)
- [48] Holt, Susanne, Janette Brand, Claire Soveny, and Jack Hansky. "Relationship of satiety to postprandial glycaemic, insulin and cholecystokinin responses." *Appetite* 18, no. 2 (1992): 129-141. [https://doi.org/10.1016/0195-6663\(92\)90190-H](https://doi.org/10.1016/0195-6663(92)90190-H)
- [49] Austin, Gregory O., and Alejandra Tomas. "Variation in responses to incretin therapy: Modifiable and non-modifiable factors." *Frontiers in Molecular Biosciences* 10 (2023): 1170181. <https://doi.org/10.3389/fmolb.2023.1170181>
- [50] Jia, Hui, Wen-Da Wu, Xi Lu, Jie Zhang, Cheng-Hua He, and Hai-Bin Zhang. "Role of glucagon-like peptide-1 and gastric inhibitory peptide in anorexia induction following oral exposure to the trichothecene mycotoxin deoxynivalenol (Vomitoxin)." *Toxicological Sciences* 159, no. 1 (2017): 16-24. <https://doi.org/10.1093/toxsci/kfx112>
- [51] Costa, Alessia, Minrong Ai, Nicolas Nunn, Isabella Culotta, Jenna Hunter, Mehdi Boutagouga Boudjadja, Lourdes Valencia-Torres et al. "Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation." *Molecular metabolism* 55 (2022): 101407. <https://doi.org/10.1016/j.molmet.2021.101407>
- [52] Trout, David L., Judith Hallfrisch, and Kay M. Behall. "Atypically high insulin responses to some foods relate to sugars and satiety." *International journal of food sciences and nutrition* 55, no. 7 (2004): 577-588. <https://doi.org/10.1080/09637480400029308>
- [53] Jazet, Ingrid M., A. Jaap Fogteloo, and A. Edo Meinders. "The relation between leptin and insulin remains when insulin secretion is disturbed." *European Journal of Internal Medicine* 17, no. 2 (2006): 109-114. <https://doi.org/10.1016/j.ejim.2005.11.003>
- [54] Chabot, François, Alexandre Caron, Mathieu Laplante, and David H. St-Pierre. "Interrelationships between ghrelin, insulin and glucose homeostasis: Physiological relevance." *World journal of diabetes* 5, no. 3 (2014): 328. <https://doi.org/10.4239/wjd.v5.i3.328>